Personal information

Activities

Employment (2)

The University of Texas at El Paso: El Paso, TX, US

2020-07-01 to present | Assistant Professor (Pharmaceutical Sciences, School of Pharmacy)
Employment
Source: Self-asserted source
Yong Qin

The University of Texas MD Anderson Cancer Center: Houston, Texas, US

2018-06 to 2020-07 | Instructor (Melanoma Medical Oncology)
Employment
Source: Self-asserted source
Yong Qin

Education and qualifications (3)

The University of Texas MD Adnerson Cancer Center: Houston, Texas, US

2016-06 to 2020-07 | Instructor (Melanoma Medical Oncology)
Qualification
Source: Self-asserted source
Yong Qin

University of Arizona: Tucson, Arizona, US

2002-08 to 2008-05 | PhD (College of Pharmacy)
Education
Source: Self-asserted source
Yong Qin

Peking Union Medical College: Beijing, CN

1999-06 to 2002-09 | MS (Chinese Academy of Medical Sciences )
Education
Source: Self-asserted source
Yong Qin

Professional activities (5)

The University of Texas MD Anderson Cancer Center: Houston, US

Trainee Excellence Award
Distinction
Source: Self-asserted source
Yong Qin

5th Annual IMMUNO-ONCOLOGY Young Investigators’ Forum: Houston, Texas, US

2019 | Top 35 Abstracts
Distinction
Source: Self-asserted source
Yong Qin

Society for Free Radical Biology and Medicine : Indianapolis, IN, US

2013-01 to 2013-12 | Professional Development Committee
Service
Source: Self-asserted source
Yong Qin

American Association for Cancer Research: Philadelphia, US

2013 | AACR‐Millennium Scholar-in-Training Award
Distinction
Source: Self-asserted source
Yong Qin

American Association for Cancer Research: Philadelphia, US

2007 | AACR-OSI Pharmaceutical Scholar-in-Training Award
Distinction
Source: Self-asserted source
Yong Qin

Funding (2)

Targeting a stress-derived immunosuppressive adenosine pathway in tumors resistant to checkpoint inhibitors

2019-08 to 2021-07 | Grant
Department of Defense Cancer Research Program (Fort Detrick, MD , US)
GRANT_NUMBER:

CA180825

Source: Self-asserted source
Yong Qin

Unlocking tumor Immunophenotype in Responders versus Non-Responders in Metastatic Uveal Melanoma Patients Receiving Immune Checkpoint Blockade

2016-09 to 2019-08 | Grant
National Cancer Institute (Md., Md., US)
Source: Self-asserted source
Yong Qin